[EN] BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS [FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE GPR119
[EN] TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS<br/>[FR] DÉRIVÉS TRICYCLIQUES DE 2,4-DIAMINO-L,3,5-TRIAZINE UTILES POUR LE TRAITEMENT DU CANCER ET DE TROUBLES MYÉLOPROLIFÉRATIFS
申请人:ASTRAZENECA AB
公开号:WO2009150462A1
公开(公告)日:2009-12-17
The present invention relates to compounds of Formula (I): (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.
BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS
申请人:Harris Joel M.
公开号:US20110065671A1
公开(公告)日:2011-03-17
The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bi-cyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.
TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS
申请人:AstraZeneca AB
公开号:EP2288602A1
公开(公告)日:2011-03-02
DIPEPTIDYL PEPTIDASE-IV INHIBITORS
申请人:Kroth Heiko
公开号:US20100009961A1
公开(公告)日:2010-01-14
The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.
Dipeptidyl Peptidase-IV Inhibitors
申请人:KROTH Heiko
公开号:US20110112051A1
公开(公告)日:2011-05-12
The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.